These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34244852)

  • 1. Erythropoiesis-independent effects of iron in chronic kidney disease.
    Patino E; Akchurin O
    Pediatr Nephrol; 2022 Apr; 37(4):777-788. PubMed ID: 34244852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
    Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
    Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepcidin in chronic kidney disease anemia.
    Santos-Silva A; Ribeiro S; Reis F; Belo L
    Vitam Horm; 2019; 110():243-264. PubMed ID: 30798815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
    Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
    Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease.
    Nakanishi T; Kimura T; Kuragano T
    Contrib Nephrol; 2019; 198():124-134. PubMed ID: 30991414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin.
    Agarwal AK; Yee J
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):298-305. PubMed ID: 31477260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond.
    Ueda N; Takasawa K
    Curr Med Chem; 2017; 24(14):1417-1452. PubMed ID: 28302014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misdistribution of iron and oxidative stress in chronic kidney disease.
    Nakanishi T; Kuragano T; Nanami M; Nagasawa Y; Hasuike Y
    Free Radic Biol Med; 2019 Mar; 133():248-253. PubMed ID: 29958932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron Metabolism in Chronic Kidney Disease Patients.
    Honda H; Hosaka N; Ganz T; Shibata T
    Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease.
    Panwar B; Gutiérrez OM
    Semin Nephrol; 2016 Jul; 36(4):252-61. PubMed ID: 27475656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease.
    Malyszko J; Malyszko JS; Matuszkiewicz-Rowinska J
    Expert Opin Ther Targets; 2019 May; 23(5):407-421. PubMed ID: 30907175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
    Jing W; Nunes ACF; Farzaneh T; Khazaeli M; Lau WL; Vaziri ND
    J Pharmacol Exp Ther; 2018 Oct; 367(1):129-137. PubMed ID: 30093458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.
    Ganz T; Nemeth E
    Semin Nephrol; 2016 Mar; 36(2):87-93. PubMed ID: 27236128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study.
    Masajtis-Zagajewska A; Nowicki M
    Ren Fail; 2018 Nov; 40(1):700-709. PubMed ID: 30741616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging effects of sevelamer in chronic kidney disease.
    Ikee R; Tsunoda M; Sasaki N; Sato N; Hashimoto N
    Kidney Blood Press Res; 2013; 37(1):24-32. PubMed ID: 23486088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.